[
  {
    "date": "2023-06-30",
    "symbol": "ATHE",
    "period": "FY",
    "cashandcashequivalents": 15773783,
    "tradeandothercurrentreceivables": 8665704,
    "othercurrentassets": 2609286,
    "currentassets": 27048773,
    "propertyplantandequipment": 61776,
    "rightofuseassets": 207087,
    "noncurrentassets": 229103,
    "assets": 27277876,
    "tradeandothercurrentpayables": 3517708,
    "currentprovisions": 308822,
    "currentleaseliabilities": 107177,
    "currenttaxliabilities": 27930,
    "currentliabilities": 4993949,
    "noncurrentprovisions": 19503,
    "noncurrentleaseliabilities": 103207,
    "noncurrentliabilities": 122710,
    "liabilities": 5116659,
    "netassetsliabilities": 22812909,
    "issuedcapital": 213971323,
    "reserveofsharebasedpayments": 3972475,
    "retainedearnings": -195782581,
    "equity": 22161217,
    "accumulateddepreciationpropertyandequipment": 181681,
    "accumulateddepreciationofrightuseofassets": 278245,
    "numberofsharesissuedandfullypaid": 2439897618,
    "revenuefrominterest": 16436,
    "otherincome": 3916333,
    "intellectualpropertyexpenses": 285067,
    "generalandadministrativeexpense": 5056571,
    "researchanddevelopmentexpense": 13198583,
    "miscellaneousotheroperatingexpense": 29404,
    "othergainslosses": 917650,
    "forfeitedoptionsfromreserves": 17150,
    "profitlossbeforetax": -13702056,
    "incometaxexpensecontinuingoperations": 104459,
    "profitloss": -13967504,
    "comprehensiveincome": -13967504,
    "basicearningslosspershare": -0.57,
    "weightedaverageshares": 2427841917,
    "dilutedearningslosspershare": -0.57,
    "adjustedweightedaverageshares": 2427841917,
    "paymentstosuppliersforgoodsandservicesandtoandonbehalfofemployees": 19943617,
    "interestreceivedclassifiedasoperatingactivities": 15798,
    "interestpaidclassifiedasoperatingactivities": 4565,
    "incometaxespaidrefund": 103453,
    "cashflowsfromusedinoperatingactivities": -20035837,
    "paymentsforrentalsecuritydeposits": 29150,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 7311,
    "cashflowsfromusedininvestingactivities": -36461,
    "proceedsfromissueofsecuritiesandotherequitysecurities": 316675,
    "paymentsforshareissuecosts": 132413,
    "principleelementsofleasepayments": 59922,
    "cashflowsfromusedinfinancingactivities": 124340,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -19947958,
    "effectofexchangeratechangesoncashandcashequivalents": 914942,
    "numberofsharesoutstanding": 2439897618,
    "issuanceofsharesnetofcostsvalue": 316675,
    "issuanceofsharesnetofcostsshares": 33023040,
    "increasedecreasethroughissuanceofoptionstoemployees": 983721,
    "increasedecreasethroughsharebasedpaymenttransactions": -132413,
    "increasedecreasethroughoptionsexpiredinsharebasedpaymentarrangement": 560014,
    "forfeitedoptionsreversedtoprofitorloss": -17150,
    "increasedecreasethroughtransactionswithowners": 1150833,
    "transactionswithownersintheircapacityasownersinshares": 33023040,
    "descriptionofaccountingpolicyforbasisofconsolidationexplanatorypolicytextblock": "(a) Principles of Consolidation",
    "descriptionofaccountingpolicyforrecognitionofotherincome": "(m) Interest income",
    "descriptionofaccountingpolicyforcomparativefiguresexplanatorypolicytextblock": "(u) Comparative Figures",
    "descriptionofaccountingpolicyfornewaccountingstandardsandinterpretationspolicytextblock": "(v) New Accounting Standards and Interpretations ",
    "disclosureoftradeandotherreceivabletabletextblock": "            Years Ended June 30,             2023      2022                            Accrued interest income      656       18       R&D tax incentive receivable (1)      8,583,635       4,669,405       Goods and services tax receivable      16,184       55,938       Accounts receivable      65,229       -       Total Trade and Other Receivables      8,665,704       4,725,361   ",
    "scheduleoftradeandotherpayabletabletextblock": "            Years Ended June 30,             2023      2022                            Trade creditors      1,716,135       2,689,098       Accrued research and development expenses      1,458,310       2,066,500       Accrued professional fees      222,126       185,362       Other accrued expenses      87,223       107,929       Other payables      33,914       57,622                              Total      3,517,708       5,106,511   ",
    "disclosureofmovementsofeachclassofprovisionexplanatorytabletextblock": "Movements in each class of provision during the financial year areset out below:",
    "scheduleofamountsnotexpectedtobesettledwithinthenext12monthstable": "The following amounts reflect leave that is notexpected to be taken or paid within the next 12 months.",
    "scheduleofreconciliationofnumberofsharesoutstandingtabletextblock": "Movements in Issued Shares",
    "scheduleofdetailsofissuanceofsharecapitaltabletextblock": "Details of share issuances are as follows:",
    "scheduleofreserveofsharebasedpaymentstabletextblock": "                  Years Ended June 30,             Notes     2023      2022      2021                                         (a) Share Based Payments                                    170,042,720 (2022: 184,692,720, 2021: 160,542,720) options for fully paid ordinary shares     11(c)      3,972,475       3,565,918       2,750,884                                                         3,972,475       3,565,918       2,750,884   ",
    "scheduleofmovementsinoptionsforfullypaidordinarysharestabletextblock": "Movements in Options for Fully Paid Ordinary Shares",
    "scheduleofamountsrelatingtoleasestabletextblock": "The statement of financial position shows the following amounts relatingto leases:",
    "disclosureofamountsrecognizedinprofitorlossrelatingleases": "The statement of profit or loss shows the following amounts relatingto leases:",
    "scheduleofoptionsoutstandingexpirydateandexercisepricestabletextblock": "Options outstanding at the end of the year have the following expirydate and exercise prices:",
    "scheduleofvaluationsofoptionsapprovedandissuedtabletextblock": "The model inputs for the valuations of options approved and issuedduring the current and previous financial years are as follows:",
    "scheduleofnumberofsharesissuedtabletextblock": "Information with respect to the number of shares issued under the stockoption plan as follows:",
    "disclosureofkeymanagementpersonnelcompensationtabletextblock": "            Years Ended June 30,             2023      2022      2021                                   Short-term employee benefits      1,727,020       1,641,015       1,891,777       Post-employment benefits      42,444       44,121       45,180       Long-term benefits      7,215       6,711       (110,285)      Termination benefits      -       -       1,000,000       Share-based payments      764,175       998,164       1,950,565              2,540,854       2,690,011       4,777,237   ",
    "scheduleofauditorremunerationtabletextblock": "            Years Ended June 30,             2023      2022      2021                                   - Audit and review of financial statements (1)      246,400       216,400       202,400       - Other audit services (2)      52,000       -       130,000                                             298,400       216,400       332,400   ",
    "scheduleofequityholdingsofkeymanagementpersonneltabletextblock": "Key Management Personnel Equity Holdings",
    "disclosureofcurrencyrisktabletextblock": "The following financial assets and liabilities are subject to foreigncurrency risk, the currency of the original amounts are displayed in brackets, all the amounts in the table below are displayed in A$at year-end spot rates:",
    "scheduleofinterestratesforclassesoffinancialassetsandliabilitiestabletextblock": "The Group’s exposure to interest rates and the effective weightedaverage interest rate for classes of financial assets and liabilities is set out below:",
    "scheduleofliquidityreservetabletextblock": "Management monitors rolling forecasts of the Group’s liquidityreserve on the basis of expected cash flows. See Note 1 (Going Concern Basis) of our accompanying financial statements.",
    "otherrevenue": 16436,
    "researchanddevelopmenttaxincentive": 3914230,
    "miscellaneousotheroperatingincome": 2103,
    "revenueandoperatingincome": 3932769,
    "employeebenefitsexpense": 2720345,
    "otherresearchanddevelopmentexpenses": 10478238,
    "depreciationexpense": 37854,
    "depreciationrightofuseassets": 64409,
    "otheremployeeexpense": 926314,
    "consultantanddirectorexpenses": 320500,
    "auditinternalcontrolandotherassuranceexpenses": 238728,
    "corporatecomplianceexpenses": 457215,
    "insuranceexpense": 721732,
    "rentalexpense": 68634,
    "administrativeexpense": 1032843,
    "sharebasedpaymentexpenses": 966571,
    "corporateadvisoryexpenses": 204621,
    "foreignexchangegainloss01": -917650,
    "currenttaxexpenseincome": 33808,
    "adjustmentsforcurrenttaxofpriorperiod": 70651,
    "taxexpenseincomeatapplicabletaxrate": -3446718,
    "taxeffectofforeigntaxrates": -6440,
    "taxeffectofresearchanddevelopmentexpenditure": 1267940,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 413976,
    "taxeffectofdeferredtaxassetnotrecognized": 1805050,
    "incometaxexpenseattributabletolossbeforeincometax": -104459,
    "deferredtaxassets": 44056899,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 3675742,
    "primafacietaxonnetlossbeforeincometax": 0.25,
    "currentaccruedincomeincludingcurrentcontractassets": 656,
    "researchanddevelopmenttaxincentivereceivable": 8583635,
    "paymentstosuppliersforgoodsandservices": 16184,
    "tradeandotherreceivables": 65229,
    "currentprepayments": 2569522,
    "othercurrentfinancialassets": 39764,
    "tradeandothercurrentpayablestotradesuppliers": 1716135,
    "accruedresearchanddevelopmentexpenses": 1458310,
    "accruedprofessionalfees": 222126,
    "othercurrentaccruedexpenses": 87223,
    "otherpayables": 33914,
    "tradeandothercurrentpayable": 3517708,
    "provisions": 328325,
    "increasedecreasethroughtransfersandotherchangesotherprovisions": 30182,
    "additionalprovisionsotherprovisions": 232747,
    "increasedecreasethroughforeignexchangefinancialassets": 8748,
    "annualleaveandlongserviceleavecarryingamount": 748705,
    "amountsexpectedtobesettledaftertwelvemonths": 19503,
    "paidordinaryshares": 213971323,
    "movementduringtheyearnoofsharesinshares": 33023040,
    "valueofincreasedecreaseinsharesoutstanding": 184262,
    "endoftheyearnoofshares": 2439897618,
    "issuedcapitalendoftheyear": 213971323,
    "increasedecreaseinnumberofshareoutstanding": 33023040,
    "issuedcapitalpreferenceshares": 184262,
    "numberofsharesissuedduringtheyear": "Security issuance costs",
    "increasedecreaseinnumberofsharesoutstanding": 23479200,
    "parvaluepershare": 0.008,
    "issuedcapitalpreferenceshare": -132413,
    "optionsforfullypaidordinaryshares1": 170042720,
    "freeattachingoptionsforfullypaidordinaryshares": 674694939,
    "numberofsharesoptionsoutstanding": 170042720,
    "sharebasedpaymentnumberofoptionsoptionsexpiredduringtheyearindollarspershare": -13150000,
    "reserveofsharebasedpaymentsexpiredduringtheyear": -560014,
    "numberofoptionsforfeitedduringtheyear": -1500000,
    "reserveofsharebasedpaymentsforfeitedduringyear": -17150,
    "expensefromsharebasedpaymenttransactionswithemployees": 983721,
    "retainedearning": 195130889,
    "profitlossattributabletoownersofparent": 13806515,
    "reclassifyexpiredoptionsfromreservesone": 560014,
    "leaseliabilities": 210384,
    "interestexpense": 4565,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 68634,
    "adjustmentsfordepreciationexpense": 37854,
    "adjustmentsfornoncashissueofequityinconsiderationofoperatingexpenses": 966571,
    "foreignexchangegainloss": -917650,
    "deferredtaxliabilityasset": 10232,
    "increasedecreaseintradeandotherreceivables": -3940343,
    "adjustmentsfordecreaseincreaseinothercurrentassets": -968207,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -1560873,
    "adjustmentsforprovisions": 78685,
    "cashonhand": 15773783,
    "cashequivalents": 15773783,
    "numberofshareoptionoutstandinginsharebasedpaymentarrangement": 170042720,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.05,
    "numberofshareoptionexpiredinsharebasedpaymentarrangement": 13150000,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement": 0.11,
    "numberofshareoptionlapsedinsharebasedpaymentarrangement": 1500000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentsarrangement": 0.02,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement": 0.05,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 87280755,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement": 0.06,
    "dateofgrantofsharebasedpaymentarrangement": "November 29, 2021",
    "expirydateofoutstandingshareoptions": "November 29, 2026",
    "exercisepriceofoutstandingshareoption1": 0.02,
    "numberofoutstandingsharesoption": 170042720,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 2.53,
    "exercisepriceshareoptionsgranted2019": 0.02,
    "sharepriceatgrantdate": 0.024,
    "yearstoexpiry": 5,
    "riskfreeinterestrate": 0.013500000000000002,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.3847,
    "fairvalueperoptions": 0.021,
    "numberofshares": 13277715,
    "basicearningslosspersharefromcontinuingoperations": -0.57,
    "weightedaveragenumberofordinarysharesonissueusedinthecalculationofbasic": 2427841917,
    "dilutedearningslosspersharefromcontinuingoperations": -0.57,
    "weightedaveragenumberofordinarysharesonissueusedinthecalculationofdiluted": 2427841917,
    "shorttermemployeebenefits": 1727020,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 42444,
    "keymanagementpersonnelcompensationotherlongtermbenefit": 7215,
    "keymanagementpersonnelcompensationsharebasedpayments": 764175,
    "keymanagementpersonnelcompensation": 2540854,
    "auditorsremunerationforauditservices": 246400,
    "auditorsremunerationforotherservices": 52000,
    "auditorsremuneration": 298400,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 1532450,
    "keymanagementpersonnelcompensationbonus": 194570,
    "otherkeymanagementpersonnel": 42444,
    "longtermbenefitslongservicesleave": 7215,
    "keymanagementpersonnelcompensationsharebasedpayment": 764175,
    "managementpersonnelcompensation": 2540854,
    "numberofshareoptionoutstanding": 21935777,
    "numberofsharesissuedother": 3555000,
    "numberofshareoptionsoutstanding": 131392720,
    "numberofshareoptionsexpired": -8750000,
    "vestedandexercisable": 68618255,
    "totalunvested": 62774465,
    "financialinstrumentstotalexposure": 13844564,
    "financialassets": -3517708,
    "averageinterestrate": 0.044000000000000004,
    "financialliabilities": -3728092,
    "tradeandotherpayables": 3728092,
    "taxrateeffectfromchangesintaxrate": "A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregateturnover of less than $20 million.",
    "eligibleamountunderthetaxincentivescheme": 3900000,
    "profitlossbeforetax1": 13806515,
    "profitlossbeforetax2": 20035837,
    "estimatedusefuleconomiclife": 20,
    "employeesdescription": "Employees",
    "taxrateeffectfromchangeintaxrate": 0.435,
    "turnoverrevenue": 20000000,
    "eligibleamountundertaxincentivescheme": 3914230,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducecurrenttaxexpense": 164311376,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducedeferredtaxexpense": 2976920,
    "eligibleamountundertaxincentiveschemes": 3363433,
    "reserveofordinaryshares": 600,
    "additionstorightofuseassets": 152817,
    "cashoutflowforleases": 133121,
    "shorttermleaseterm": "12 months",
    "terminationnoticeperiodforresearchanddevelopmentcontracts": 30,
    "researchanddevelopmentterminationcommitments": 3700000,
    "numberofdirector": 4,
    "numberofpreviousdirector": 2,
    "numberofemployees": 9,
    "numberofkeymanagementpersonnel": 3,
    "percentageofdefaultvestingconditionsperyear": 0.25,
    "proportionofownershipinterestinsubsidiary": 1,
    "professionalfeesexpense": 202800,
    "numberofreportablesegment": 1,
    "averageannualmovementforeignexchangerate": 0.036000000000000004,
    "sensitivityanalysisofposttaxprofitimpactofpercentchangeinaustraliandollaragainstusdollar": 499159,
    "cash": 15473231,
    "percentageofinterestrate": 0.0385,
    "entityregistrantname": "ALTERITY THERAPEUTICS LIMITED",
    "tradingsymbol": "ATHE",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "June 30",
    "entitycommonstocksharesoutstanding": 2439897618,
    "amendmentflag": "false",
    "entitycentralindexkey": 1131343,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "June 30, 2023",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "000-49843",
    "entityincorporationstatecountrycode": "Australia",
    "entityaddressaddressline1": "Level 14, 350 Collins Street",
    "entityaddresscityortown": "Melbourne",
    "entityaddresspostalzipcode": 3000,
    "entityaddresscountry": "Australia",
    "contactpersonnelname": "David Stamler",
    "cityareacode": 61,
    "localphonenumber": "3 9349 4906",
    "security12btitle": "American Depositary Shares, each representing 600 Ordinary Shares",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentfinstmterrorcorrectionflag": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "PricewaterhouseCoopers",
    "auditorlocation": "Australia",
    "auditorfirmid": 1379
  },
  {
    "date": "2022-06-30",
    "symbol": "ATHE",
    "period": "FY",
    "cashandcashequivalents": 34806799,
    "tradeandothercurrentreceivables": 4725361,
    "othercurrentassets": 1611929,
    "currentassets": 41144089,
    "propertyplantandequipment": 102551,
    "rightofuseassets": 115971,
    "noncurrentassets": 218522,
    "assets": 41362611,
    "tradeandothercurrentpayables": 5079587,
    "currentprovisions": 284390,
    "currentleaseliabilities": 57632,
    "currenttaxliabilities": 26924,
    "currentliabilities": 5820410,
    "noncurrentprovisions": 13753,
    "noncurrentleaseliabilities": 59857,
    "noncurrentliabilities": 73610,
    "liabilities": 5894020,
    "netassetsliabilities": 35468591,
    "issuedcapital": 213787061,
    "reserveofsharebasedpayments": 3565918,
    "retainedearnings": -181884388,
    "equity": -181884388,
    "accumulateddepreciationpropertyandequipment": 202380,
    "accumulateddepreciationofrightuseofassets": 312156,
    "numberofsharesissuedandfullypaid": 2406874578,
    "revenuefrominterest": 2504,
    "otherincome": 5123525,
    "intellectualpropertyexpenses": 364665,
    "generalandadministrativeexpense": 5513915,
    "researchanddevelopmentexpense": 14745776,
    "miscellaneousotheroperatingexpense": 1156,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 2722430,
    "profitlossbeforetax": -12777053,
    "incometaxexpensecontinuingoperations": 70008,
    "profitloss": -12847061,
    "comprehensiveincome": -12847061,
    "basicearningslosspershare": -0.53,
    "weightedaverageshares": 2405990036,
    "dilutedearningslosspershare": -0.53,
    "adjustedweightedaverageshares": 2405990036,
    "paymentstosuppliersforgoodsandservicesandtoandonbehalfofemployees": 16875144,
    "interestreceivedclassifiedasoperatingactivities": 2755,
    "proceedsfromresearchanddevelopmenttaxrefund": 4126364,
    "interestpaidclassifiedasoperatingactivities": 2285,
    "othergrantreceived": 454120,
    "incometaxespaidrefund": 43084,
    "cashflowsfromusedinoperatingactivities": -12337274,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 89147,
    "cashflowsfromusedininvestingactivities": -89147,
    "proceedsfromexerciseofoptionsandissueofsecurities": 17176040,
    "paymentsforshareissuecosts": 836969,
    "principleelementsofleasepayments": 34513,
    "cashflowsfromusedinfinancingactivities": 16304558,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 3878137,
    "effectofexchangeratechangesoncashandcashequivalents": 2813146,
    "numberofsharesoutstanding": 2406874578,
    "issuanceofsharesnetofcostsvalue": 17176040,
    "issuanceofsharesnetofcostsshares": 322857900,
    "increasedecreasethroughissuanceofoptionstoemployees": 1179577,
    "increasedecreasethroughissuanceofoptionstoconsultants": 326544,
    "increasedecreasethroughsharebasedpaymenttransactions": -836969,
    "increasedecreasethroughoptionsexpiredinsharebasedpaymentarrangement": 240310,
    "forfeitedoptionsofvestedoptionsreversedtoaccumulateddeficit": 450777,
    "increasedecreasethroughtransactionswithowners": 17845192,
    "transactionswithownersintheircapacityasownersinshares": 322857900,
    "disclosureofbackgroundandsignificantaccountingpoliciestextblock": "1. BACKGROUNDAND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ",
    "disclosureofrevenueandotherincomefromcontinuingoperationsexplanatorytextblock": "2. INTERESTAND OTHER INCOME FROM CONTINUING OPERATIONS ",
    "accumulateddeficitduringdevelopmentstagetextblock": "12. ACCUMULATEDDEFICIT DURING DEVELOPMENT STAGE ",
    "descriptionofaccountingpolicyforbasisofconsolidationexplanatorypolicytextblock": "(a) Principlesof Consolidation ",
    "descriptionofaccountingpolicyforrecognitionofotherincome": "(m)Interest income ",
    "descriptionofaccountingpolicyforcomparativefiguresexplanatorypolicytextblock": "(u) ComparativeFigures ",
    "descriptionofaccountingpolicyfornewaccountingstandardsandinterpretationspolicytextblock": "(v) NewAccounting Standards and Interpretations  ",
    "disclosureoftradeandotherreceivabletabletextblock": "            Years    Ended June 30,             2022      2021                                                 Accrued interest income      18       269       R&D tax incentive receivable      4,669,405       4,126,364       Goods and services tax receivable      55,938       47,706       Payroll tax receivable      -       103,338       Total Trade and Other    Receivables      4,725,361       4,277,677    ",
    "scheduleoftradeandotherpayabletabletextblock": "            Years    Ended June 30,             2022      2021                            Trade creditors      2,689,098       1,448,546       Accrued research and development expenses      2,066,500       714,677       Accrued professional fees      185,362       155,797       Other accrued expenses      107,929       149,644       Other payables      57,622       33,845                              Total      5,106,511       2,502,509   ",
    "scheduleofamountsnotexpectedtobesettledwithinthenext12monthstable": "                Years    Ended June 30,                     2022              2021                                                Long service leave obligation expected    to be settled after 12 months              13,753                   9,768       ",
    "scheduleofreserveofsharebasedpaymentstabletextblock": "                   Years    Ended June 30,             Notes      2022      2021      2020                                          (a)    Share Based Payments                                  184,692,720 (2021: 160,542,720, 2020: 21,550,000) options for fully paid ordinary shares      11(c)      3,565,918       2,750,884       866,121                                                             3,565,918       2,750,884       866,121    ",
    "scheduleofnumberofsharesissuedtabletextblock": "            Years    Ended June 30,             2022      2021      2020             Number    of Shares      Number    of Shares      Number    of Shares       Beginning of the year      13,277,715       13,277,715       13,277,715       Issued during the year      -       -       -                                      End of the financial year      13,277,715       13,277,715       13,277,715    ",
    "disclosureofkeymanagementpersonnelcompensationtabletextblock": "            Years    Ended June 30,             2022      2021      2020                                   Short-term employee benefits      1,641,015       1,891,777       1,549,861       Post-employment benefits      44,121       45,180       48,947       Long-term benefits      6,711       (110,285)      20,528       Termination benefits      -       1,000,000       -       Share-based payments      998,164       1,950,565       -              2,690,011       4,777,237       1,619,336   ",
    "usefullivesordepreciationratepropertyplantandequipments": 0.33,
    "operatingleaseincome": 111811,
    "discountedusinglesseesincrementalborrowingrate": 108028,
    "lessshorttermleasenotrecognizedasliability": -13290,
    "leaseliabilityrecognized": 94738,
    "currentleaseliability": 77665,
    "noncurrentleaseliability": 17073,
    "noncurrentleaseliabilitytotal": 94738,
    "rightofuseofassetincreasedby": 88477,
    "leaseliabilityincreased": 94738,
    "netimpactonretainedearningsdecreasevalue": -6261,
    "otherrevenue": 2504,
    "researchanddevelopmenttaxincentive": 4669405,
    "othergrant": 454120,
    "revenueandoperatingincome": 5126029,
    "employeebenefitsexpenseunderresearchanddevelopment": 2517516,
    "researchanddevelopmentexpenseother": 12228260,
    "depreciationexpense": 17848,
    "depreciationrightofuseassets": 36366,
    "employeebenefitsexpense": 705541,
    "consultantanddirectorexpenses": 390896,
    "auditinternalcontrolandotherassuranceexpenses": 220798,
    "corporatecomplianceexpenses": 401741,
    "insuranceexpense": 655990,
    "rentalexpense": 79329,
    "otheradministrativeandofficeexpenses": 911347,
    "sharebasedpaymentexpenses": 1506122,
    "corporateadvisoryexpenses": 587937,
    "foreignexchangegainloss": -2813635,
    "currenttaxexpenseincome": 50072,
    "adjustmentsforcurrenttaxofpriorperiod": 19936,
    "taxexpenseincomeatapplicabletaxrate": -3194263,
    "taxeffectofforeigntaxrates": -9712,
    "taxeffectofresearchanddevelopmentexpenditure": 1516215,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 529075,
    "taxeffectofdeferredtaxassetnotrecognized": 1108614,
    "incometaxexpenseattributabletolossbeforeincometax": 70008,
    "deferredtaxassets": 41204149,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 2903797,
    "primafacietaxonnetlossbeforeincometax": 0.25,
    "currentaccruedincomeincludingcurrentcontractassets": 18,
    "researchanddevelopmenttaxincentivereceivable": 4669405,
    "goodsandservicestaxreceivable": 55938,
    "currentprepayments": 1601697,
    "currentassetsother": 10232,
    "tradeandothercurrentpayablestotradesuppliers": 2689098,
    "accruedresearchanddevelopmentexpenses": 2066500,
    "accruedprofessionalfees": 185362,
    "othercurrentaccruedexpenses": 107929,
    "otherpayables": 57622,
    "tradeandothercurrentpayable": 5106511,
    "provisions": 298143,
    "increasedecreasethroughtransfersandotherchangesotherprovisions": 25210,
    "additionalprovisionsotherprovisions": 327,
    "provisionschangeinforeignexchange": 14437,
    "annualleaveandlongserviceleavecarryingamount": 670020,
    "amountsexpectedtobesettledaftertwelvemonths": 13753,
    "paidordinaryshares": 213787061,
    "movementduringtheyearnoofsharesinshares": 322857900,
    "valueofincreasedecreaseinsharesoutstanding": 16339071,
    "endoftheyearnoofshares": 2406874578,
    "issuedcapitalendoftheyear": 213787061,
    "numberofsharesissuedduringtheyear": "Security issuance costs",
    "increasedecreaseinnumberofsharesoutstanding": 322857900,
    "parvaluepershare": 0.053,
    "issuedcapitalpreferenceshares": 16339071,
    "reserveofsharebasedpayment": 3565918,
    "reserveofsharebasedpaymentsshares": 184692720,
    "reserveofwarrantspaymentsshares": 674694939,
    "numberofsharesoptionsoutstanding": 184692720,
    "numberofwarrantsissued": 45150000,
    "sharebasedpaymentexpense": -7000000,
    "reserveofsharebasedpaymentsexpenseduringyear": -240310,
    "numberofoptionsforfeitedduringtheyear": -14000000,
    "reserveofsharebasedpaymentsforfeitedduringyear": -450777,
    "expensefromsharebasedpaymenttransactionswithemployees": 1506121,
    "retainedearning": 181884388,
    "profitlossattributabletoownersofparent": 12847061,
    "reclassifyexpiredoptionsfromreservesone": 240310,
    "reclassifyforfeitedoptionsfromreserves": -450777,
    "leaseliabilities": 117489,
    "interestexpense": 2285,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 79309,
    "adjustmentsfordepreciationexpense": 17848,
    "otherinflowsoutflowsofnoncashclassifiedasfinancingactivities": 61,
    "adjustmentsfornoncashissueofequityinconsiderationofoperatingexpenses": 1506122,
    "increasedecreaseintradeandotherreceivables": -447684,
    "adjustmentsfordecreaseincreaseinothercurrentassets": -516176,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 2604001,
    "adjustmentsforprovisions": 122884,
    "cashonhand": 34806799,
    "cashequivalents": 34806799,
    "numberofshareoptionoutstandinginsharebasedpaymentarrangement": 184692720,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.09,
    "numberofshareoptionissuedinsharebasedpaymentarrangement": 45150000,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement": 0.04,
    "numberofshareoptionexpiredinsharebasedpaymentarrangement": -7000000,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement": 0.07,
    "numberofshareoptionlapsedinsharebasedpaymentarrangement": -14000000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentsarrangement": 0.09,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement": 0.05,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 60150000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement": 0.09,
    "dateofgrantofsharebasedpaymentarrangement": "December 18, 2017",
    "expirydateofoutstandingshareoptions": "November 29, 2026",
    "exercisepriceofoutstandingshareoption1": 0.02,
    "numberofoutstandingsharesoption": 184692720,
    "exercisepriceshareoptionsgranted2019": 0.02,
    "sharepriceatgrantdate": 0.024,
    "yearstoexpiry": 5,
    "riskfreeinterestrate": 0.013500000000000002,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.3847,
    "fairvalueperoptions": 0.021,
    "numberofshares": 13277715,
    "basicearningslosspersharefromcontinuingoperations": -0.53,
    "weightedaveragenumberofordinarysharesonissueusedinthecalculationofbasic": 2405990036,
    "dilutedearningslosspersharefromcontinuingoperations": -0.53,
    "weightedaveragenumberofordinarysharesonissueusedinthecalculationofdiluted": 2405990036,
    "shorttermemployeebenefits": 1641015,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 23568,
    "keymanagementpersonnelcompensationotherlongtermbenefit": 6711,
    "keymanagementpersonnelcompensationsharebasedpayments": 998164,
    "keymanagementpersonnelcompensation": 1983815,
    "auditorsremunerationforauditservices": 216400,
    "auditorsremuneration": 216400,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 1641015,
    "longtermbenefitslongservicesleave": 6711,
    "keymanagementpersonnelcompensationsharebasedpayment": 998164,
    "numberofshareoptionoutstanding": 18380777,
    "numberofshareoptionsoutstanding": 913927200,
    "numberofshareoptionsgrantedasremuneration": 5000000,
    "numberofshareoptionsexpired": -4500000,
    "numberofshareoptionsforfeited": -14000000,
    "vestedandexercisable": 43750000,
    "totalunvested": 96392720,
    "financialinstrumentstotalexposure": 27171142,
    "financialassets": 39532160,
    "averageinterestrate": 0.00002,
    "financialliabilities": -5224000,
    "tradeandotherpayables": 5224000,
    "taxrateeffectfromchangesintaxrate": "A 43.5% refundable tax offset will be availableto eligible small companies with an annual aggregate turnover of less than $20 million.",
    "eligibleamountunderthetaxincentivescheme": 4700000,
    "profitlossbeforetax1": 12847061,
    "profitlossbeforetax2": 12337274,
    "othercashandcashequivalents": 34806799,
    "saleofsharesvalue": 17176040,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 4669405,
    "estimatedusefuleconomiclife": 20,
    "turnoverrevenue": 20000000,
    "eligibleamountundertaxincentivescheme": 4669405,
    "taxrateeffectfromchangeintaxrate": 0.435,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducecurrenttaxexpense": 153026530,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducedeferredtaxexpense": 2976920,
    "eligibleamountundertaxincentiveschemes": 3363433,
    "additionstorightofuseassets": 86353,
    "cashoutflowforleases": 116107,
    "shorttermleaseterm": "12 months",
    "leasecommitmentswithinoneyear": "one year",
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 9857,
    "leasecommitmentsexpirydate": "September 30, 2022",
    "terminationnoticeperiodforresearchanddevelopmentcontracts": 30,
    "researchanddevelopmentterminationcommitments": 5200000,
    "numberofdirector": 4,
    "numberofpreviousdirector": 2,
    "numberofkeymanagementpersonnel": 2,
    "numberofemployees": 10,
    "numberofconsultant": 4,
    "percentageofdefaultvestingconditionsperyear": 0.25,
    "proportionofownershipinterestinsubsidiary": 1,
    "professionalfeesexpense": 37500,
    "averageannualmovementforeignexchangerate": 0.0819,
    "sensitivityanalysisofposttaxprofitimpactofpercentchangeinaustraliandollaragainstusdollar": 2233871,
    "cash": 20233747,
    "percentageofinterestrate": 0.0015,
    "entityregistrantname": "ALTERITYTHERAPEUTICS LIMITED",
    "tradingsymbol": "ATHE",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "June 30",
    "entitycommonstocksharesoutstanding": 2406874578,
    "amendmentflag": "false",
    "entitycentralindexkey": 1131343,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "June 30, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "000-49843",
    "entityincorporationstatecountrycode": "Australia",
    "entityaddressaddressline1": "Level3, 460 Bourke Street",
    "entityaddresscityortown": "Melbourne",
    "entityaddresspostalzipcode": 3000,
    "entityaddresscountry": "Australia",
    "contactpersonnelname": "DavidStamler",
    "cityareacode": 61,
    "localphonenumber": "3 9349 4906",
    "security12btitle": "American Depositary Shares, each representing sixty Ordinary Shares",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "auditorname": "PricewaterhouseCoopers",
    "auditorlocation": "Australia",
    "auditorfirmid": 1379
  },
  {
    "date": "2021-06-30",
    "symbol": "ATHE",
    "period": "FY",
    "cashandcashequivalents": 28115516,
    "tradeandothercurrentreceivables": 4277677,
    "othercurrentassets": 1095753,
    "currentassets": 33488946,
    "propertyplantandequipment": 31313,
    "rightofuseassets": 65495,
    "noncurrentassets": 96808,
    "assets": 33585754,
    "tradeandothercurrentpayables": 2502509,
    "currentprovisions": 537368,
    "currentleaseliabilities": 27746,
    "currentliabilities": 3067623,
    "noncurrentprovisions": 9768,
    "noncurrentleaseliabilities": 37903,
    "noncurrentliabilities": 47671,
    "liabilities": 3115294,
    "netassetsliabilities": 30470460,
    "issuedcapital": 197447990,
    "reserveofsharebasedpayments": 2750884,
    "retainedearnings": -169728414,
    "equity": 30470460,
    "accumulateddepreciationpropertyandequipment": 374064,
    "accumulateddepreciationofrightuseofassets": 272491,
    "numberofsharesissuedandfullypaid": 2084016678,
    "revenuefrominterest": 20676,
    "otherincome": 4485225,
    "intellectualpropertyexpenses": 360026,
    "generalandadministrativeexpense": 6937842,
    "researchanddevelopmentexpense": 12283848,
    "miscellaneousotheroperatingexpense": 2227,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -297111,
    "forfeitedoptionsfromreserves": 65800,
    "profitlossbeforetax": -15309353,
    "profitloss": -15309353,
    "comprehensiveincome": -15309353,
    "basicanddilutedearningslosspershare": -0.9,
    "weightedaveragenumberofordinarysharesusedincomputingbasicanddilutednetlosspers": 1696876324,
    "paymentstosuppliersforgoodsandservicesandtoandonbehalfofemployees": 17720622,
    "interestreceivedclassifiedasoperatingactivities": 20491,
    "interestpaidclassifiedasoperatingactivities": 1299,
    "othergrantreceived": 213235,
    "covidnineteengovernmentrelief": 158126,
    "cashflowsfromusedinoperatingactivities": -17330069,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 10472,
    "cashflowsfromusedininvestingactivities": -10472,
    "proceedsfromexerciseofoptionsandissueofsecurities": 39236886,
    "paymentsforshareissuecosts": 2492650,
    "principleelementsofleasepayments": 58289,
    "cashflowsfromusedinfinancingactivities": 36685947,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 19345406,
    "effectofexchangeratechangesoncashandcashequivalents": -426782,
    "numberofsharesoutstanding": 2084016678,
    "increasedecreasethroughissuanceofoptionstoemployees": 1950563,
    "issuanceofsharesnetofcostsvalue": 39236886,
    "issuanceofsharesnetofcostsshares": 1046658646,
    "increasedecreasethroughsharebasedpaymenttransactions": -2492650,
    "forfeitedoptionsreversedtoprofitorloss": -65800,
    "increasedecreasethroughtransactionswithowners": 36744236,
    "transactionswithownersintheircapacityasownersinshares": 1046658646,
    "disclosureofbackgroundandsignificantaccountingpoliciestextblock": "1. BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTINGPOLICIES",
    "disclosureofrevenueandotherincomefromcontinuingoperationsexplanatorytextblock": "2. INTEREST AND OTHER INCOME FROM CONTINUING OPERATIONS",
    "disclosureofaccumulateddeficitduringdevelopmentstagetextblock": "12. ACCUMULATED DEFICIT DURING DEVELOPMENT STAGE",
    "descriptionofaccountingpolicyforbasisofconsolidationexplanatorypolicytextblock": "(a) Principles of Consolidation",
    "descriptionofaccountingpolicyforrecognitionofotherincome": "m) Interestincome<p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left\">Other income is made up of interest income whichis recognised on a time proportion basis using the effective interest method.</p><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left\"> </p>",
    "descriptionofaccountingpolicyforcomparativefiguresexplanatorypolicytextblock": "(u) Comparative Figures",
    "descriptionofaccountingpolicyfornewaccountingstandardsandinterpretationspolicytextblock": "(v) New Accounting Standards and Interpretations",
    "disclosureoftradeandotherreceivabletabletextblock": "Years Ended June 30,             2021      2020                                                 Accrued interest income      269       12,584       R&D tax incentive receivable      4,126,364       -       Goods and services tax receivable      47,706       48,737       Payroll tax receivable      103,338       -       Total Trade and Other Receivables      4,277,677       61,321",
    "scheduleoftradeandotherpayabletabletextblock": "Years Ended June 30,             2021      2020                            Trade creditors      1,448,546       954,033       Accrued research and development expenses      714,677       843,419       Accrued professional fees      155,797       187,199       Other accrued expenses      149,644       73,991       Other payables      33,845       10,962                              Total      2,502,509       2,069,604",
    "scheduleofamountsnotexpectedtobesettledwithinnext12monthstabletextblock": "Years Ended June 30,             2021      2020                            Long service leave obligation expected to be settled after 12 months      9,768       41,514",
    "scheduleofreserveofsharebasedpaymentstabletextblock": "Years Ended June 30,             Notes     2021      2020      2019                                         (a) Share Based Payments                                 160,542,720 (2020: 21,550,000, 2019: 25,300,000) options for fully paid ordinary shares     11(c)      2,750,884       866,121       1,158,975                                                         2,750,884       866,121       1,158,975",
    "scheduleofamountsrelatingtoleasestabletextblock": "Years Ended June 30,       Right-of-use assets     2021      2020      2019       Right-of-use assets      65,495       31,866       -       Lease liabilities                              Current      27,746       32,879       -       Non-current      37,903       868       -              65,649       33,747       -",
    "disclosureofamountsrecognizedinprofitorlossrelatingleases": "Years Ended June 30,             2021      2020      2019       Depreciation of right-of-use assets      56,707       86,439            -       Interest expense      1,299       3,877       -       Expenses relating to short-term leases (included in general and administration expenses)      87,131       46,913       -       Expenses relating to variable lease payments not included in lease liabilities (included in general and administration expenses)      -       25,844       -",
    "scheduleofnumberofsharesissuedtabletextblock": "Years Ended June 30,             2021      2020      2019             Number of Shares      Number of Shares      Number of Shares       Beginning of the year      13,277,715       13,277,715       13,277,715       Issued during the year      -       -       -                                      End of the financial year      13,277,715       13,277,715       13,277,715",
    "disclosureofkeymanagementpersonnelcompensationtabletextblock": "Years Ended June 30,             2021      2020      2019                                   Short-term employee benefits      1,891,777       1,549,861       2,046,496       Post-employment benefits      45,180       48,947       41,062       Long-term benefits      (110,285)      20,528       23,016       Termination benefits      1,000,000       -       -       Share-based payments      1,950,565       -       20,443              4,777,237       1,619,336       2,131,017",
    "scheduleofauditorremunerationtabletextblock": "Years Ended June 30,             2021      2020      2019                                   - Audit and review of financial statements (1)      202,400       194,900       210,422       - Other audit services (2)      130,000       60,000       90,000                                             332,400       254,900       300,422",
    "disclosureofcurrencyrisktabletextblock": "Consolidated Entity             2021      2020             A$      A$       Cash and cash equivalents (USD)      21,523,678       5,403,402       Cash and cash equivalents (€EUR)      -       -       Cash and cash equivalents (£GBP)      442       430       Trade and other payables (USD)      (819,812)      (562,710)      Trade and other payables (€EUR)      (1,901)      (12,245)      Trade and other payables (£GBP)      (124,863)      (4,337)      Total exposure      20,577,544       4,824,540",
    "usefullivesordepreciationratepropertyplantandequipments": 0.05,
    "operatingleaseincome": 111811,
    "discountedusinglesseesincrementalborrowingrate": 108028,
    "lessshorttermleasenotrecognizedasliability": -13290,
    "leaseliabilityrecognized": 94738,
    "currentleaseliability": 77665,
    "noncurrentleaseliability": 17073,
    "noncurrentleaseliabilitytotal": 94738,
    "rightofuseofassetincreasedby": 88477,
    "leaseliabilityincreased": 94738,
    "netimpactonretainedearningsdecreasevalue": -6261,
    "otherrevenue": 20676,
    "researchanddevelopmenttaxincentive": 4126364,
    "relieffund": 145626,
    "othergrant": 213235,
    "revenueandoperatingincome": 4505901,
    "employeebenefitsexpenseunderresearchanddevelopment": 2169420,
    "researchanddevelopmentexpenseother": 10114428,
    "depreciationexpense": 18662,
    "depreciationrightofuseassets": 56707,
    "employeebenefitsexpense": 1556078,
    "consultantanddirectorexpenses": 852369,
    "auditinternalcontrolandotherassuranceexpenses": 220198,
    "corporatecomplianceexpenses": 692895,
    "insuranceexpense": 531877,
    "rentalexpense": 87612,
    "otheradministrativeandofficeexpenses": 718520,
    "sharebasedpaymentexpenses": 1950563,
    "corporateadvisoryexpenses": 252361,
    "foreignexchangegainloss": 426782,
    "taxexpenseincomeatapplicabletaxrate": -3980432,
    "taxeffectofforeigntaxrates": -11344,
    "taxeffectofresearchanddevelopmentexpenditure": 1393478,
    "researchanddevelopmentexpenses": 2976920,
    "currenttaxexpenseincomeandadjustmentsforcurrenttaxofpriorperiods": 1764370,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 628535,
    "taxeffectofdeferredtaxassetnotrecognized": 3182313,
    "deferredtaxassets": 41223341,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 4549151,
    "primafacietaxonnetlossbeforeincometax": 0.26,
    "currentaccruedincomeincludingcurrentcontractassets": 269,
    "researchanddevelopmenttaxincentivereceivable": 4126364,
    "goodsandservicestaxreceivable": 47706,
    "currentvalueaddedtaxreceivables": 103338,
    "currentprepayments": 1086391,
    "currentassetsother": 9362,
    "tradeandothercurrentpayablestotradesuppliers": 1448546,
    "accruedresearchanddevelopmentexpenses": 714677,
    "accruedprofessionalfees": 155797,
    "othercurrentaccruedexpenses": 149644,
    "otherpayables": 33845,
    "provisions": 273876,
    "increasedecreasethroughtransfersandotherchangesotherprovisions": 231981,
    "additionalprovisionsotherprovisions": 231061,
    "provisionschangeinforeignexchange": -12404,
    "annualleaveandlongserviceleavecarryingamount": 547136,
    "amountsexpectedtobesettledaftertwelvemonths": 9768,
    "issuedcapitalamount": 197447990,
    "numberofshareoutstanding": 2084016678,
    "issuedcapitalbeginningoftheyear": 160703754,
    "increasedecreaseinnumberofsharesoutstanding": 1046658646,
    "valueofincreasedecreaseinsharesoutstanding": 36744236,
    "issuedcapitalendoftheyear": 197447990,
    "parvaluepershare": 0.033,
    "issueofsharesunderatmfacility": 1562055,
    "issueofsharestosophisticatedandprofessionalinvestors": 10036287,
    "securityissuancecosts": -2492650,
    "totalamountofshareissuance": 36744236,
    "reserveofsharebasedpayment": 2750884,
    "numberofshareoptionsoutstanding": 160542720,
    "numberofwarrantsissued": 140392720,
    "reserveofwarrantsissuedduringyear": 1950563,
    "numberofshareoptionsforfeited": -1400000,
    "reserveofsharebasedpaymentsforfeitedduringyear": -65800,
    "retainedearning": 169728414,
    "profitlossattributabletoownersofparent": 15309353,
    "leaseliabilities": 65649,
    "interestexpense": 1299,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 87131,
    "adjustmentsfordepreciationexpense": 18662,
    "otherinflowsoutflowsofnoncashclassifiedasfinancingactivities": -145,
    "adjustmentsfornoncashissueofequityinconsiderationofoperatingexpenses": 1884763,
    "increasedecreaseintradeandotherreceivables": -4216356,
    "adjustmentsfordecreaseincreaseinothercurrentassets": -517617,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 432905,
    "adjustmentsforprovisions": -106417,
    "cashonhand": 28115516,
    "numberofshareoptionoutstandinginsharebasedpaymentarrangement": 160542720,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.1,
    "numberofshareoptionissuedinsharebasedpaymentarrangement": 140392720,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement": 0.05,
    "numberofshareoptionlapsedinsharebasedpaymentarrangement": -1400000,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentsarrangement": 0.11,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement": 0.06,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 69150000,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement": 0.09,
    "dateofgrantofsharebasedpaymentarrangement": "June 7, 2017",
    "expirydateofoutstandingshareoptions": "June 6, 2022",
    "exercisepriceofoutstandingshareoption1": 0.07,
    "numberofoutstandingsharesoption": 7000000,
    "exercisepriceshareoptionsgranted2019": 0.26,
    "sharepriceatgrantdate": 0.16,
    "yearstoexpiry": "P5Y",
    "riskfreeinterestrate": 0.02,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.748,
    "fairvalueperoptions": 0.083,
    "numberofshares": 13277715,
    "dilutedearningslosspershare": -0.9,
    "weightedaveragenumberofordinarysharesonissueusedinthecalculationofbasicanddiluted": 1696576324,
    "shorttermemployeebenefits": 1891777,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 45180,
    "keymanagementpersonnelcompensationotherlongtermbenefit": -110285,
    "terminationbenefits": 1000000,
    "keymanagementpersonnelcompensationsharebasedpayments": 1950565,
    "keymanagementpersonnelcompensation": 4777237,
    "auditorsremunerationforauditservices": 202400,
    "auditorsremunerationforotherservices": 130000,
    "auditorsremuneration": 332400,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 66209,
    "longtermbenefitslongservicesleave": -121542,
    "terminationbenefit": 1000000,
    "keymanagementpersonnelcompensationsharebasedpayment": 225389,
    "numberofshareoptionoutstanding": 18011000,
    "numberofshareoptionsgrantedasremuneration": 14000000,
    "optionsvested": 14000000,
    "outstandingatyearsend": 19000000,
    "vestedandexercisable": 19000000,
    "totalunvested": 91392720,
    "financialinstrumentstotalexposure": 21523678,
    "financialassets": 3231661,
    "averageinterestrate": 0.0001,
    "financialliabilities": -2502509,
    "tradeandotherpayables": 2502509,
    "taxrateeffectfromchangesintaxrate": "A 43.5% refundable tax offset will be available to eligible small companies with an annual aggregateturnover of less than $20 million.",
    "eligibleamountunderthetaxincentivescheme": 4100000,
    "profitlossbeforetax1": -15309353,
    "profitlossbeforetax2": -17330069,
    "othercashandcashequivalents": 28115516,
    "interestreceivableandotherassets": 4126364,
    "estimatedusefuleconomiclife": "P3Y",
    "employeesdescription": "The measurement date for share-based payments issued to employees is the grant date, being the dateat which a shared understanding of the terms and conditions of the arrangement is reached. However, if an issuance to an employee is subjectto shareholder approval because it exceeds the 15% threshold per ASX Listing Rule 7.1, then the measurement date of these share-basedpayments is the date at which the share-based payments are approved by shareholders.",
    "taxrateeffectfromchangeintaxrate": 0.435,
    "turnoverrevenue": 20000000,
    "eligibleamountundertaxincentivescheme": 4126364,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducecurrenttaxexpense": 147101619,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducedeferredtaxexpense": 2976920,
    "eligibleamountundertaxincentiveschemes": 3363433,
    "additionstorightofuseassets": 90336,
    "cashoutflowforleases": 146719,
    "shorttermleaseterm": "12 months",
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 30668,
    "leasecommitmentsexpirydate": "2021-09-30",
    "terminationnoticeperiodforresearchanddevelopmentcontracts": "P30D",
    "researchanddevelopmentterminationcommitments": 4500000,
    "numberofdirector": 6,
    "numberofpreviousdirector": 2,
    "numberofkeymanagementpersonnel": 2,
    "numberofemployees": 8,
    "numberofconsultant": 5,
    "percentageofdefaultvestingconditionsperyear": 0.25,
    "proportionofownershipinterestinsubsidiary": 1,
    "professionalfeesexpense": 101400,
    "averageannualmovementforeignexchangerate": 0.0916,
    "sensitivityanalysisofposttaxprofitimpactofpercentchangeinaustraliandollaragainstusdollar": 1896923,
    "cash": 3231661,
    "percentageofinterestrate": 0.0001,
    "entityregistrantname": "ALTERITY THERAPEUTICS LIMITED",
    "tradingsymbol": "ATHE",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--06-30",
    "entitycommonstocksharesoutstanding": 2084016678,
    "amendmentflag": "false",
    "entitycentralindexkey": 1131343,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2021-06-30",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "000-49843",
    "entityincorporationstatecountrycode": "C3",
    "entityaddressaddressline1": "Level 3, 460 Bourke Street",
    "entityaddresscityortown": "Melbourne",
    "entityaddresspostalzipcode": 3000,
    "entityaddresscountry": "AU",
    "contactpersonnelname": "David Stamler",
    "cityareacode": 61,
    "localphonenumber": "3 9348 0377",
    "security12btitle": "American Depositary Shares, each representing sixty Ordinary Shares",
    "securityexchangename": "NASDAQ",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards"
  },
  {
    "date": "2020-06-30",
    "symbol": "ATHE",
    "period": "FY",
    "entityregistrantname": "ALTERITY THERAPEUTICS LTD",
    "entitycentralindexkey": 1131343,
    "amendmentflag": "false",
    "documentfiscalperiodfocus": "FY",
    "currentfiscalyearenddate": "--06-30",
    "documenttype": "20-F",
    "documentperiodenddate": "2020-06-30",
    "documentfiscalyearfocus": 2020,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 1037358032,
    "entityfilenumber": "000-49843",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityinteractivedatacurrent": "Yes",
    "entityincorporationstatecountrycode": "C3",
    "cashandcashequivalents": 9196892,
    "tradeandothercurrentreceivables": 61321,
    "othercurrentassets": 578136,
    "currentassets": 9836349,
    "propertyplantandequipment": 39503,
    "rightofuseassets": 88477,
    "noncurrentassets": 71369,
    "assets": 9907718,
    "tradeandothercurrentpayables": 2069604,
    "currentprovisions": 326679,
    "currentleaseliabilities": 77665,
    "currentliabilities": 2714522,
    "noncurrentprovisions": 41514,
    "noncurrentleaseliabilities": 17073,
    "noncurrentliabilities": 42382,
    "liabilities": 2756904,
    "netassetsliabilities": 7150814,
    "issuedcapital": 160703754,
    "reserveofsharebasedpayments": 2320480,
    "retainedearnings": -154419061,
    "equity": -154419061,
    "accumulateddepreciationpropertyandequipment": 355955,
    "accumulateddepreciationofrightuseofassets": 215875,
    "numberofsharesissuedandfullypaid": 1037358032,
    "revenuefrominterest": 17117,
    "otherincome": 122729,
    "intellectualpropertyexpenses": 352922,
    "generalandadministrativeexpense": 3446139,
    "researchanddevelopmentexpense": 10098439,
    "miscellaneousotheroperatingexpense": 44217,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 333055,
    "forfeitedoptionsfromreserves": 12016,
    "profitlossbeforetax": -13456800,
    "profitloss": -13456800,
    "comprehensiveincome": -13456800,
    "basicanddilutedearningslosspershare": -1.5,
    "weightedaverageshares": 894872224,
    "paymentstosuppliersforgoodsandservicesandtoandonbehalfofemployees": 14363974,
    "interestreceivedclassifiedasoperatingactivities": 19162,
    "proceedsfromresearchanddevelopmenttaxrefund": 4824880,
    "interestpaidclassifiedasoperatingactivities": 3878,
    "covidnineteengovernmentrelief": 92688,
    "cashflowsfromusedinoperatingactivities": -9431122,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 16744,
    "cashflowsfromusedininvestingactivities": -16744,
    "proceedsfromexerciseofoptionsandissueofsecurities": 4363886,
    "paymentsforshareissuecosts": 292768,
    "principleelementsofleasepayments": 89241,
    "cashflowsfromusedinfinancingactivities": 3981877,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -5465989,
    "effectofexchangeratechangesoncashandcashequivalents": 262977,
    "numberofsharesoutstanding": 18607443,
    "initialadoptionofifrs": -6261,
    "restatedtotalequityatbeginningoffinancialperiod": -141243099,
    "restatedtotalequityatbeginningoffinancialperiodshares": 860837432,
    "issuanceofsharesnetofcostsvalue": 4363886,
    "issuanceofsharesnetofcostsshares": 176520600,
    "increasedecreasethroughsharebasedpaymenttransactions": -292768,
    "increasedecreasethroughoptionsexpiredinsharebasedpaymentarrangement": 280838,
    "forfeitedoptionsreversedtoprofitorloss": -12016,
    "increasedecreasethroughtransactionswithowners": 280838,
    "totaltransactionswithownersintheircapacityasownersshares": 176520600,
    "usefullivesordepreciationratepropertyplantandequipments": 0.33,
    "operatingleaseincome": 111811,
    "discountedusinglesseesincrementalborrowingrate": 108028,
    "lessshorttermleasenotrecognizedasliability": 13290,
    "leaseliabilityrecognized": 94738,
    "leaseliabilities": 94738,
    "leaseliabilityincreased": 94738,
    "netimpactonretainedearningsdecreasevalue": -6261,
    "eligibleamountundertaxincentivescheme": 3363433,
    "cashflowsfromusedinoperatingactivitiescontinuingoperations": 9431122,
    "taxrateeffectfromchangeintaxrate": 0.435,
    "turnoverrevenue": 20000000,
    "descriptionofrefundabletaxoffsetrate": "Under the proposed amendments, the refundable tax offset rate for companies with an aggregated turnover of less than $20 million would become 41% and the maximum refund would be capped at $4m (exclusive of expenditure incurred relating to clinical trial activities).",
    "leaseliabilitiespercentage": 0.052,
    "usefullivesordepreciationratepropertyplantandequipment": "3 to 20 years",
    "amortisationmethodintangibleassetsotherthangoodwill": "straight-line basis",
    "usefullivesoramortisationrateintangibleassetsotherthangoodwill": "five years",
    "periodofpaymentoftradeandotherpayables": "P30D",
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 35075,
    "otherrevenue": 17117,
    "relieffund": 122729,
    "revenueandoperatingincome": 139846,
    "employeebenefitsexpenseunderresearchanddevelopment": 2698139,
    "researchanddevelopmentexpenseother": 7400300,
    "depreciationexpense": 25988,
    "depreciationrightofuseassets": 86439,
    "employeebenefitsexpense": 617889,
    "professionalfeesexpense": 742390,
    "auditinternalcontrolandotherassuranceexpenses": 217506,
    "corporatecomplianceexpenses": 384705,
    "insuranceexpense": 628060,
    "rentalexpense": 72757,
    "administrativeexpense": 670405,
    "taxexpenseincomeatapplicabletaxrate": -3700620,
    "taxeffectofforeigntaxrates": -18308,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 148105,
    "taxeffectofdeferredtaxassetnotrecognized": 3570823,
    "deferredtaxassets": 40133912,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": 1793626,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducecurrenttaxexpense": 145941499,
    "periodofcarriedforwardfortaxlosses": "P20Y",
    "primafacietaxonnetlossbeforeincometax": 0.275,
    "currentaccruedincome": 12584,
    "currentvalueaddedtaxreceivables": 48737,
    "currentprepayments": 567884,
    "currentassetsother": 10252,
    "tradeandothercurrentpayablestotradesuppliers": 954033,
    "accruedresearchanddevelopmentexpenses": 843419,
    "accruedprofessionalfees": 187199,
    "othercurrentaccruedexpenses": 73991,
    "otherpayables": 10962,
    "provisions": 368193,
    "increasedecreasethroughtransfersandotherchangesotherprovisions": -62991,
    "additionalprovisionsotherprovisions": 40017,
    "provisionusedotherprovisions": 240734,
    "provisionschangeinforeignexchange": 1604,
    "annualleaveandlongserviceleavecarryingamount": 653553,
    "amountsexpectedtobesettledaftertwelvemonths": 41514,
    "sharesofissuedcapital": 160703754,
    "increasedecreaseinnumberofsharesoutstanding": 137945160,
    "valueofincreasedecreaseinsharesoutstanding": 4071118,
    "parvaluepershare": 0.025,
    "shareissuerelatedcost": 292768,
    "issueofsharesunderatmfacility": 3483792,
    "numberofshareoptionsoutstanding": 13250000,
    "numberofwarrantsexpired": -586672964,
    "numberofshareoptionsexpired": -3400000,
    "numberofshareoptionsforfeited": -350000,
    "reserveofsharebasedpaymentsexpiredduringyear": -280838,
    "reserveofsharebasedpaymentsforfeitedduringyear": -12016,
    "numberofoutstandingshareoptions": 21550000,
    "expirydateofoutstandingshareoptions": "31 January 2023",
    "impactofinitialadoptionofifrs16": 6261,
    "reclassifyexpiredoptionsfromreserves": 280838,
    "interestexpense": 3877,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 46913,
    "expenserelatingtovariableleasepaymentsnotincludedinmeasurementofleaseliabilities": 25844,
    "additionstorightofuseassets": 29827,
    "cashoutflowforleases": 165875,
    "shorttermleaseterm": "12 months or less.",
    "adjustmentsfordepreciationexpense": 25988,
    "adjustmentsfornoncashissueofequityinconsiderationofoperatingexpenses": -12016,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 4768176,
    "adjustmentsfordecreaseincreaseinothercurrentassets": 53633,
    "adjustmentsforincreasedecreaseintradeandotherpayables": -648570,
    "adjustmentsforincreasedecreaseinothercurrentliabilities": -1577,
    "adjustmentsforprovisions": 16582,
    "cashonhand": 9196892,
    "termofnoncancellablepropertylease": "P3M",
    "terminationnoticeperiodforresearchanddevelopmentcontracts": "P30D",
    "researchanddevelopmentterminationcommitments": 2000000,
    "leaseexpire": "2020-12-17",
    "numberofshareoptionoutstandinginsharebasedpaymentarrangement": 21550000,
    "numberofshareoptionexpiredinsharebasedpaymentarrangement": -3400000,
    "numberofshareoptionlapsedinsharebasedpaymentarrangement": -350000,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 21550000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement": 0.1,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement": 0.25,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentsarrangement": 0.07,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement": 0.1,
    "dateofgrantofsharebasedpaymentarrangement": "October 3, 2014",
    "exercisepriceofoutstandingshareoption1": 0.08,
    "numberofoutstandingsharesoption": 700000,
    "weightedaverageremainingcontractuallifeofoptionsoutstandingatendofperiod": "P2Y3M15D",
    "exercisepriceshareoptionsgranted2019": 0.34,
    "sharepriceatgrantdate": 0.22,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.305,
    "yearstoexpiry": "P4Y",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0271,
    "numberofpreviousdirector": 2,
    "numberofdirector": 4,
    "numberofkeymanagementpersonnel": 2,
    "numberofemployees": 9,
    "numberofconsultant": 5,
    "optionexpirationperiod": "P10Y",
    "percentageofdefaultvestingconditionsperyear": 0.25,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 625470,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 21003,
    "keymanagementpersonnelcompensationotherlongtermbenefit": 8066,
    "keymanagementpersonnelcompensation": 625470,
    "auditorsremunerationforauditservices": 194900,
    "auditorsremunerationforotherservices": 60000,
    "auditorsremuneration": 254900,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 12462,
    "keymanagementpersonnelcompensationterminationbenefits": 1000000,
    "noticeperiodoftermination": "P30D",
    "periodbywhichterminationbenefittobepaid": "P30D",
    "vestedandexercisable": 13250000,
    "proportionofownershipinterestinsubsidiary": 1,
    "financialinstrumentstotalexposure": 4824540,
    "financialassets": 3716309,
    "financialliabilities": -33747,
    "averageinterestrate": 0.0024,
    "averageannualmovementforeignexchangerate": 0.0217,
    "sensitivityanalysisofposttaxprofitimpactofpercentchangeinaustraliandollaragainstusdollar": 105090,
    "percentageofinterestrate": 0.0012,
    "termdepositperiod": "P3M",
    "maturitydate": "2020-09-11"
  },
  {
    "date": "2019-06-30",
    "symbol": "ATHE",
    "period": "FY",
    "entityregistrantname": "ALTERITY THERAPEUTICS LTD",
    "entitycentralindexkey": 1131343,
    "amendmentflag": "false",
    "documentfiscalperiodfocus": "FY",
    "currentfiscalyearenddate": "--06-30",
    "documenttype": "20-F",
    "documentperiodenddate": "2019-06-30",
    "documentfiscalyearfocus": 2019,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "entityextransitionperiod": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 860837432,
    "entityfilenumber": "000-49843",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityinteractivedatacurrent": "No",
    "entityincorporationstatecountrycode": "C3",
    "cashandcashequivalents": 14399904,
    "tradeandothercurrentreceivables": 4829497,
    "othercurrentassets": 631769,
    "currentassets": 19861170,
    "propertyplantandequipment": 48748,
    "noncurrentassets": 48748,
    "assets": 19909918,
    "tradeandothercurrentpayables": 2718174,
    "currentprovisions": 356191,
    "currentliabilities": 3320169,
    "noncurrentprovisions": 34976,
    "noncurrentliabilities": 34976,
    "liabilities": 3355145,
    "netassetsliabilities": 16554773,
    "issuedcapital": 156632636,
    "reserveofsharebasedpayments": 1158975,
    "retainedearnings": -141236838,
    "equity": -141236838,
    "accumulateddepreciationpropertyandequipment": 329824,
    "numberofsharesissuedandfullypaid": 860837432,
    "revenuefrominterest": 108538,
    "otherincome": 4951167,
    "intellectualpropertyexpenses": 322097,
    "generalandadministrativeexpense": 4308352,
    "researchanddevelopmentexpense": 12983185,
    "miscellaneousotheroperatingexpense": 132965,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 349064,
    "profitlossbeforetax": -12337830,
    "profitloss": -12337830,
    "comprehensiveincome": -12337830,
    "basicanddilutedearningslosspershare": -2,
    "weightedaverageshares": 615772236,
    "paymentstosuppliersforgoodsandservicesandtoandonbehalfofemployees": 17325579,
    "interestreceivedclassifiedasoperatingactivities": 119089,
    "proceedsfromresearchanddevelopmenttaxrefund": 3251672,
    "cashflowsfromusedinoperatingactivities": -13954818,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 7022,
    "cashflowsfromusedininvestingactivities": -7022,
    "proceedsfromexerciseofoptionsandissueofsecurities": 13084629,
    "paymentsforshareissuecosts": 362320,
    "cashflowsfromusedinfinancingactivities": 12722309,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -1239531,
    "effectofexchangeratechangesoncashandcashequivalents": 403879,
    "numberofsharesoutstanding": 18607443,
    "issuanceofsharesnetofcostsvalue": 13084629,
    "issuanceofsharesnetofcostsshares": 326945962,
    "valueofsharesissuedunderpurchaseplan": 89138,
    "increasedecreasethroughsharebasedpaymenttransactions": -362321,
    "increasedecreasethroughoptionsexpiredinsharebasedpaymentarrangement": 684117,
    "increasedecreasethroughtransactionswithowners": 684117,
    "usefullivesordepreciationratepropertyplantandequipments": 0.33,
    "eligibleamountundertaxincentivescheme": 5000000,
    "cashflowsfromusedinoperatingactivitiescontinuingoperations": 13894101,
    "taxrateeffectfromchangeintaxrate": 0.435,
    "turnoverrevenue": 20000000,
    "cashpositiondecreased": 14399904,
    "tradeandotherreceivables": 4825270,
    "leaseliabilities": 108525,
    "usefullivesordepreciationratepropertyplantandequipment": "three to 20 years",
    "amortisationmethodintangibleassetsotherthangoodwill": "straight-line basis",
    "usefullivesoramortisationrateintangibleassetsotherthangoodwill": "five years",
    "periodofpaymentoftradeandotherpayables": "P30D",
    "minimumleasepaymentpayableundernoncancellableoperatinglease": 17085,
    "otherrevenue": 108538,
    "researchanddevelopmenttaxincentive": 4951167,
    "revenueandoperatingincome": 5059705,
    "employeebenefitsexpenseunderresearchanddevelopment": 2645512,
    "researchanddevelopmentexpenseother": 10337673,
    "depreciationexpense": 29696,
    "employeebenefitsexpense": 735775,
    "professionalfeesexpense": 52000000,
    "auditinternalcontrolandotherassuranceexpenses": 208972,
    "corporatecomplianceexpenses": 470294,
    "insuranceexpense": 448769,
    "rentalexpense": 132836,
    "administrativeexpense": 804641,
    "percentageoftaxoffsetincentiveforeligibleexpenditure": 0.435,
    "taxexpenseincomeatapplicabletaxrate": -3392903,
    "taxeffectofforeigntaxrates": 19045,
    "taxeffectofresearchanddevelopmentexpenditure": 1688887,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 145245,
    "taxeffectofdeferredtaxassetnotrecognized": 1539726,
    "deferredtaxassets": 35913682,
    "temporarydifferencesassociatedwithinvestmentsinsubsidiariesbranchesandassociatesandinterestsinjointventures": -1119563,
    "taxbenefitarisingfrompreviouslyunrecognisedtaxlosstaxcreditortemporarydifferenceofpriorperiodusedtoreducecurrenttaxexpense": 130709461,
    "periodofcarriedforwardfortaxlosses": "P20Y",
    "primafacietaxonnetlossbeforeincometax": 0.275,
    "currentaccruedincome": 2129,
    "researchanddevelopmenttaxincentivereceivable": 4825270,
    "currentvalueaddedtaxreceivables": 2098,
    "currentprepayments": 621737,
    "currentassetsother": 10032,
    "tradeandothercurrentpayablestotradesuppliers": 1693885,
    "accruedresearchanddevelopmentexpenses": 752156,
    "accruedprofessionalfees": 181378,
    "othercurrentaccruedexpenses": 79035,
    "otherpayables": 11720,
    "provisions": 391167,
    "additionalprovisionsotherprovisions": 68045,
    "provisionusedotherprovisions": 328715,
    "annualleaveandlongserviceleavecarryingamount": 636971,
    "amountsexpectedtobesettledaftertwelvemonths": 34976,
    "sharesofissuedcapital": 156632636,
    "increasedecreaseinnumberofsharesoutstanding": 269905533,
    "valueofincreasedecreaseinsharesoutstanding": 12722308,
    "parvaluepershare": 0.04,
    "shareissuerelatedcost": -362320,
    "issueofsharesunderatmfacility": 43544,
    "issueofsharesunderstrategicinvestmentbylifebiosciencesllc": 10526318,
    "issueofsharestosophisticatedandprofessionalinvestors": 913807,
    "newordinarysharesissued": 7962060,
    "numberofshareoptionsoutstanding": 13250000,
    "numberofshareoptionsissued": 2450000,
    "numberofwarrantsissued": 586672964,
    "numberofshareoptionsexpired": -2366490,
    "reserveofsharebasedpaymentsissuedduringyear": 30370,
    "reserveofsharebasedpaymentsexpiredduringyear": -684117,
    "reserveofsharebasedpaymentsexpenseduringyear": 58768,
    "numberofoutstandingshareoptions": 586672964,
    "expirydateofoutstandingshareoptions": "31 January 2023",
    "reclassifyexpiredoptionsfromreserves": 684117,
    "adjustmentsfordepreciationexpense": 29696,
    "adjustmentsfornoncashissueofequityinconsiderationofoperatingexpenses": 89138,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -1677087,
    "adjustmentsfordecreaseincreaseinothercurrentassets": -365144,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 662926,
    "adjustmentsforprovisions": 47362,
    "cashonhand": 14399904,
    "numberofnoncancellableleases": 2,
    "termofnoncancellablepropertylease": "P24M",
    "terminationnoticeperiodforresearchanddevelopmentcontracts": "P30D",
    "researchanddevelopmentterminationcommitments": 2300000,
    "numberofshareoptionoutstandinginsharebasedpaymentarrangement": 25300000,
    "numberofshareoptionissuedinsharebasedpaymentarrangement": 2450000,
    "numberofshareoptionexpiredinsharebasedpaymentarrangement": -2366490,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 25300000,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement": 0.12,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement": 0.1,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement": 0.87,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement": 0.12,
    "dateofgrantofsharebasedpaymentarrangement": "April 7, 2014",
    "exercisepriceofoutstandingshareoption1": 0.08,
    "numberofoutstandingsharesoption": 700000,
    "exercisepriceshareoptionsgranted2019": 0.25,
    "sharepriceatgrantdate": 0.23,
    "descriptionofexpectedvolatilityshareoptionsgranted": 2.894,
    "yearstoexpiry": "P4Y",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0302,
    "numberofpreviousdirector": 2,
    "numberofdirector": 4,
    "numberofkeymanagementpersonnel": 2,
    "numberofemployees": 11,
    "numberofconsultant": 7,
    "optionexpirationperiod": "P10Y",
    "percentageofdefaultvestingconditionsperyear": 0.25,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 236665,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 20531,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 15222,
    "keymanagementpersonnelcompensationsharebasedpayment": 20443,
    "keymanagementpersonnelcompensation": 272418,
    "auditorsremunerationforauditservices": 279622,
    "auditorsremunerationforinternalcontrols": 20800,
    "auditorsremuneration": 300422,
    "keymanagementpersonnelcompensationterminationbenefits": 1000000,
    "noticeperiodoftermination": "P30D",
    "periodbywhichterminationbenefittobepaid": "P30D",
    "numberofshareoptionsgrantedasremuneration": 1250000,
    "increasedecreaseinnumberofshareoptionsoutstanding": -2500000,
    "vestedandexercisable": 13250000,
    "proportionofownershipinterestinsubsidiary": 1,
    "financialinstrumentstotalexposure": -35242,
    "financialassets": 9726016,
    "financialliabilities": -2718174,
    "averageinterestrate": 0.0042,
    "periodforaverageannualmovementinforeignexchangerate": "P5Y",
    "averageannualmovementforeignexchangerate": 0.0636,
    "sensitivityanalysisofposttaxprofitimpactofpercentchangeinaustraliandollaragainstusdollar": 542116,
    "percentageofinterestrate": 0.02,
    "termdepositperiod": "P3M"
  }
]